Form 8-K - Current report:
SEC Accession No. 0001628280-25-013619
Filing Date
2025-03-19
Accepted
2025-03-18 19:49:57
Documents
13
Period of Report
2025-03-12
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-20250312.htm   iXBRL 8-K 46615
  Complete submission text file 0001628280-25-013619.txt   174759

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arwr-20250312.xsd EX-101.SCH 1812
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arwr-20250312_lab.xml EX-101.LAB 22548
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arwr-20250312_pre.xml EX-101.PRE 13066
15 EXTRACTED XBRL INSTANCE DOCUMENT arwr-20250312_htm.xml XML 2829
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 25750400
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)